Multi-million pound biotech campus launches in Tees Valley
A new multi-million pound biotech campus has been launched by a global firm in Tees Valley.
Biotech development and manufacturing specialist FUJIFILM Diosynth Biotechnologies has officially launched its new Billingham BioCampus.
The firm, which specialises in biopharmaceutical development, has invested £2.6m into the new facility.
Phase 1 of the recently completed development includes a 42,000 sq ft office space and visitor centre, with land also made ready for subsequent construction phases, which are expected to include additional research and development laboratories and new manufacturing facilities.
The project, supported by £3.6m from the Tees Valley Mayor and Combined Authority, has safeguarded 150 jobs and created a further 22.
Tees Valley Mayor Ben Houchen commented: “FUJIFILM Diosynth Biotechnologies is a massive asset to not just our biologics sector but to our region as a whole and this is just the latest good news story to come out of the business. Our investment into its expansion represents how vital it is and I’m delighted this first phase has now been completed.
“I’ve been working closely with FUJIFILM ever since my first Far East trade mission in 2018, when I visited the firm’s head offices to reaffirm our support for the company and see how we could work together in the future.
“We’re seeing the result of its confidence in our area now, with news that even more game-changing cash will be invested into the site, bringing more jobs and expansion.”
Paul Found, chief operating officer of FUJIFILM Diosynth Biotechnologies - UK, added: “We are very happy to have reached this day and formally announce the completion of this project as we embark on additional expansions right here in the North East of England.
“We are so proud of being a part of an industry that is dedicated to making life-impacting medicines a reality.”
Looking to promote your product/service to SME businesses in your region? Find out how Bdaily can help →
Enjoy the read? Get Bdaily delivered.
Sign up to receive our daily bulletin, sent to your inbox, for free.